Zoetis Recently won 2 awards for Industry-leading Innovation at 2016 Animal Pharm Awards Competition
Thursday, January 19, 2017
Posted by: Kate Oesterle
Zoetis recently won two awards for industry-leading innovation in the 2016 Animal Pharm Awards competition. Animal Pharm, the most widely read newsletter reporting on the animal health industry, announced the award winners on January 17.
Zoetis was recognized with top honors in the categories of Best New Product – Companion Animal for the monoclonal antibody therapy CYTOPOINT™ and Best New Product Portfolio for a portfolio of new canine products launched in 2016, including CYTOPOINT™, Simparica® (sarolaner) and VANGUARD® vaccines.
Animal Pharm's annual industry awards are designed to honor achievements within the animal health sector over the calendar year. Subscribers can nominate companies, products and employees in 12 award categories. A panel of judges comprised of industry experts evaluate the nominations and select the winners.
Zoetis' wins in the Best New Product categories speak to the high caliber of the company's research and development program.
Winning Best New Product – Companion Animal, CYTOPOINT™ was developed by Zoetis scientists as the first caninized monoclonal antibody licensed in the United States to help reduce clinical signs such as itching associated with atopic dermatitis in dogs of any age. It neutralizes interleukin – 31 (IL - 31), a protein responsible for triggering itch in dogs. Zoetis scientists confirmed the role of IL-31 in canine atopic dermatitis. The idea that targeting and neutralizing IL-31 with an antibody approach, spurred the design and development of this unique, caninized antibody.
Read full article.